43 results about "Memory Dysfunction" patented technology

The nasal cavity administrated huperzine preparation consists of huperzine as effective medicine component, lauryl azatroketone and other infiltration promoter and other assistants. It is used for treating senile dementia and memory dysfunction and raising memory and learning capacity. It has high mucous membrane penetrating property and high brain targeting property and each administration can lead 80-500 microgram of huperzine into body.

The invention discloses an application of tungstate lithium for preparing a medicine, in particular an application for preparing drug for treating neurodegenerative disease, neuropathy caused by diabetes, and cerebral ischemia including cerebral dysfunction. Both of activity of anion and cation of the tungstate lithium can perform synergistic reaction to inhibit activity of a GSK-3 much better. By inhibiting activity of a GSK-3 alpha, generation of the A beta is reduced to decrease SP; by inhibiting activity of a GSK-3 beta, hyperphosphorylation of tau protein is inhibitted to reduce NFT. Thereby, survival and wound repair of neurocyte are promoted even in a state of ischemia and anoxia to improve learning and memory dysfunction by increasing content of BDNF in cortical neurons.

The invention relates to a building method and application of an STCH (stress and chaperone) gene knock-out animal model. The model can function as an animal model for the research of occurrence of depression and / or dementia. The model is prepared by using a gene knock-out technique, animal behavior detections show that a mouse suffers depression-like symptoms (forced swimming test and tail suspension test) and memory dysfunction (water maze test) while it grows older and has depression and dementia-like symptoms, and the model is applicable to screening anti-depression and anti-dementia drugs.

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and also analyzing the gene expression profile from leukocytes and comparing the value of the subject's biomarker profile (lipidomic profile plus gene expression profile) with the value of a normal biomarker profile. A change in the value of the subject's biomarker profile, including a change in the subject's biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

The invention relates to the use of ginsenosides in the preparation of foods and drugs for preventing age-associated memory decline and Alzheimer's disease-related memory impairment. The experiments confirm that the ginsenosides can significantly improve the passive avoidance ability, the active avoidance ability and the space memory exploration ability of mice and have the obvious function of preventing the age-associated memory decline and the Alzheimer's disease-related memory impairment by giving the ginsenosides to C57BL / 6J mice and SAMP8 mice from the animal middle-aged period to the old-aged period of the C57BL / 6J mice or the time which should occur the Alzheimer's disease-related memory impairment of the SAMP8 mice.

The invention provides an application of polygala alkaline hydrolysis product composition in preparation of an anti-senile dementia medicine. The polygala alkaline hydrolysis product composition comprises the following main components by weight percentage: 25-38% of tenuifolin, 10 to 25% of fallaxsaponin A, 12 to 25% of 3, 4, 5-trimethoxycinnamic acid (TMCA) and 5-15% of p-methoxycinnamic acid (PMCA). The polygala alkaline hydrolysis product composition can obviously improve learning and memory impairment of a C57 mouse caused by hippocampal injection of Alpha Beta 25-35 and can obviously improve the spatial learning and memory capability of a C57 mouse model suffering from the learning and memory impairment caused by scopolamine, with an effect superior to that of a positive medicine, as well as can obviously improve the spatial learning and memory capability and the passive avoiding capability of a rapidly-aging C57 mouse model suffering from the learning and memory impairment.

The invention relates to a composition for improving memory. The composition is formed by uniformly mixing sesamin powder extracted from sesame seed meal and astragaloside powder extracted from raidx astragali, wherein the ratio of the sesamin powder to the astragaloside powder is 1-2:1-2; the sesamin content of the sesamin powder is over 50 percent; and the astragaloside content of the astragaloside powder is over 50 percent. A pharmacological test indicates that the composition has the effect of improving the learning and memory functions of an aging animal model, can act synergetic enhancement on physiological activity and improves respective learning and memory improving functions well; and a toxicological test indicates that the composition is safe to apply. The composition of the invention can be used for preparing health-care food and medicaments for assisting in improving the memory and can improve learning and memory dysfunction and coordination dysfunction caused by degenerative diseases of central nervous system, such as Alzheimer disease, Parkinsonism and the like.

The invention relates to a composition medicine used for curing senile dementia and a preparation method thereof, which uses ginkgo leaves and salvia miltiorrhiza as raw materials. The raw materials are processed by soaking for extraction at low temperature, refining of column absorption, cooling and drying for obtaining extracts; then appropriate amount of pharmaceutic adjuvant are added for preparing pharmaceutical preparations of formulations allowed by various pharmaceutics by the common technique. The invention has explicit pharmic composition, advanced technique and definite curative effects; the medicine prepared by the invention and used as the medicine for providing nutrition to protect cranial nerves and preventing degenerative brain aging has obvious effects; the effects of the medicine are obviously stronger than using the ginkgo leaves or the salvia miltiorrrhiza alone; the compatible medication has addition and synergetic effect; the medicine has excellent effects on curing the senile dementia, learning and memory dysfunction and the brain aging, etc.

The invention discloses a traditional Chinese medicine composition and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from rhizoma coptidis, cortex phellodendri, fructus gardeniae, radix salviae miltiorrhizae, turmeric root and rhizoma acori tatarinowii. The traditional Chinese medicine composition can significantly relieve the learning and memory dysfunction of 5 multiplied by FAD transgenic mice, reduce the expression of Abeta40 / 42 in hippocampus, increase the expression levels of presynaptic and postsynaptic protein in the hippocampusof 5 multiplied by FAD transgenic mice, relieve excitatory synaptic transmission disorder in the hippocampus of 5 multiplied by FAD mice, and meanwhile inhibit apoptosis of hippocampal neurons and proliferation of microglia in 5 multiplied by FAD mice; and in addition, the traditional Chinese medicine composition can inhibit expression of serum and hippocampal inflammatory factors in 5 multipliedby FAD mice, and therefore, a reliable theoretical basis is provided for the preparation of medicines from the traditional Chinese medicine composition for treatment or adjuvant treatment of Alzheimer's disease or preparation of health care products related to Alzheimer's disease from the traditional Chinese medicine composition.

The invention discloses application of heterophyllin B in improving memory and / or preventing the Alzheimer's disease, particularly discloses the memory enhancement function of a radix pseudostellariae aqueous extract, radix pseudostellariae cyclopeptide extract and heterophyllin B for normal mice and the amelioration function on learning and memory dysfunction of dementia mice by injecting Abeta1-42 to the paracele, and discusses the action mechanism of the heterophyllin B. Results show that the radix pseudostellariae aqueous extract, the radix pseudostellariae cyclopeptide extract and the heterophyllin B can significantly enhance the cognitive memory ability of the normal mice and ameliorate the memory impairment of the dementia model mice, the regeneration of cerebral cortex neurites is promoted, and cortical neuron loss and neurite atrophy which are induced by Abeta are prevented; results prompt that the heterophyllin B, a radix pseudostellariae solution and a cyclopeptide extract may reconstruct the neural circuit network by promoting the regeneration of the neurites to play the memory improvement role, and the heterophyllin B can be used for preparing drugs or health foods for preventing and treating the Alzheimer's disease.

The invention relates to an application of icaritin to a medicine for treating the Alzheimer disease. Icaritin is taken as a main raw herb, and a proper amount of auxiliary materials are added to prepare an oral preparation or an injection. By deep and detailed research of icaritin on aspects, such as a pharmacological action and an action mechanism, it is found that icaritin can obviously reduce Abeta aggregation and cholinergic nerve functional impairment, due to Abeta<25-35>, of a dementia rat model, and obviously improves the learning and memory dysfunction of the dementia rat model. Icaritin can reduce Abeta aggregation and improves the function of brain cholinergic nerve, produces a function of resisting Abeta<25-35> neurotoxicity, and obviously improves the learning and memory ability of the dementia rat model. According to the invention, by researching the effects of icaritin on the learning and memory ability, the cholinergic system, and an Abeta metabolic pathway of the dementia rat model, the pharmacological action mechanism of icaritin on treating the Alzheimer disease is illustrated, and pharmacological foundations on application of further developing icaritin are provided.

A crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, or named (S)-oxiracetam, is provided, which is characterized by a powder x-ray diffraction pattern that exhibits data of d-values versus the relative intensities as: 7.075(M), 5.355(S), 5.092(S), 4.590(M), 4.325(M), 4.259(S), 4.041(VS), 3.808(M), 3.542(M), 3.445(M), 3.393(M), 2.972(M), 2.914(S). A method for preparing a crystal form I of (S)-oxiracetam is also provided, which includes preparing the crude product and crystallizing A use of the crystal form I of (S)-oxiracetam in the manufacture of a medicament for preventing and treating memory dysfunction is also provided. Accordingly, the crystal form I of (S)-oxiracetam prepared by the method has high purity of more than 99.3% based on the percentages of the mass, with better efficacy than (S)-oxiracetam for preventing or treating memory dysfunction. Concerning the way of charging materials, adding inorganic base only a few times is simpler and more beneficial to industrial manufacturing and application.

The present invention relates to an Agathobaculum sp. strain having prophylactic or therapeutic effects on autism spectrum disorders, and use thereof. When the intestinal microorganism Agathobaculum sp. strain of the present invention was orally administered to valproic acid (VPA)-induced autism model mice and BTBR autism model mice, the effects of remarkably improving autism spectrum disorders including repetitive behaviors, hyperactivity, social deficiency and cognitive / memory dysfunction of the mice were observed, as compared with a non-treated control. Accordingly, it may be usefully applied to foods, drugs, or feeds for preventing or treating autism spectrum disorders, and thus is very useful in the relevant industries.

The present invention relates to a composition for preventing or treating a cognitive impairment-related disease, which includes mumefural, and more particularly, to a pharmaceutical composition; a health functional food composition; and a feed composition respectively for preventing or treating a cognitive impairment-related disease; a health functional food composition for enhancing learning ability, cognitive function, or memory, each composition including mumefural or an acceptable salt thereof as an active ingredient; and a method of treating a cognitive impairment-related disease using the pharmaceutical composition.Due to excellent effects of the mumefural of the present invention on normalizing damage to the brain (i.e., basal forebrain, white matter, hippocampus, etc.) and excellent effects thereof on enhancing memory, the mumefural of the present invention may be effectively used to treat neurodegenerative diseases (i.e., dementia, Alzheimer's disease, etc.) and cognitive impairment caused by brain damage (i.e., memory impairment), and may be used to enhance learning ability, cognitive function, and memory.

The invention discloses an artificially synthesized polypeptide fragment NYEPPTVVPGGDL, also discloses an application of the artificially synthesized polypeptide fragment NYEPPTVVPGGDL in preparation of a medicine for preventing and treating memory dysfunction caused by beta amyloid peptide 25-35 (A beta 25-35), and belongs to the field of pharmacy. By establishing a nerve injury cell model for giving A beta 25-35 stimulation to rat adrenal chromaffin tumor (PC12) cells, it is found that the peptide fragment can significantly improve the survival rate of the cells and the like; and in a mouse memory dysfunction model in which A beta 25-35 is injected into unilateral hippocampus, the peptide fragment is found to be capable of remarkably improving the memory dysfunction of mice. Therefore, the peptide fragment can be used for preparing medicines for preventing and treating nerve injury and memory dysfunction caused by beta amyloid peptide 25-35 (A beta 25-35), comprising medicines for preventing and treating Alzheimer's disease.

The invention provides a target lncRNA: MSTRG.27033.1 for learning and memory dysfunction caused by microwave radiation. The target comprises at least one of the following sequences: an RNA sequence as shown in SEQ ID NO: 1; or an RNA sequence having at least 70% identity with the RNA sequence as shown in SEQ ID NO: 1, or an RNA sequence having at least 80% identity with the RNA sequence as shown in SEQ ID NO: 1, or an RNA sequence having at least 85% identity with the RNA sequence as shown in SEQ ID NO: 1, or an RNA sequence having at least 90% identity with the RNA sequence as shown in SEQ ID NO: 1, or an RNA sequence having at least 95% identity with the RNA sequence as shown in SEQ ID NO: 1, or an RNA sequence having at least 99% of identity with the RNA sequence as shown in SEQ ID NO: 1.

The invention discloses application of phenylpyruvic acid in preparation of products for relieving or improving anxiety and depression behaviors. The invention provides new application of phenylpyruvic acid or its pharmaceutically acceptable salts or phenylpyruvic acid prodrugs in preparation of products for preventing, alleviating and / or treating affective mental disorder diseases, or improving learning and memory dysfunction. The invention provides a powerful technical theoretical basis for application of phenylpyruvic acid in the aspects of resisting anxiety, resisting depression, and improving the learning and memory ability level, and on the other hand also solves the problems of adverse effects in anti-anxiety and anti-depression drugs and drugs for improving learning and memory ability. Moreover, the adding amount of phenylpyruvic acid is small, phenylpyruvic acid can be directly added into animal drinking water, feed, food or drugs, has the advantages of safety, effectiveness,no cause of toxic and side effects and the like, and has good popularization and application prospects in resisting anxiety, resisting depression, and improving the learning and memory ability level.

Peripherally administered Brefeldin A and its analogs and derivatives are used to enhance learning and reverse memory dysfunction through induced long term potentiation in hippocampal issues.

The invention discloses a composition with a memory improving effect and a preparation method thereof. The composition is prepared from 5-15 parts of fructus lycii, 2-8 parts of ginseng, 15-25 parts of poria cocos, 5-15 parts of rhizoma polygonati, 5-15 parts of lily, 5-15 parts of sea-buckthorn, 5-12 parts of fingered citron, 8-16 parts of nepenia, 10-20 parts of spina date seed, 5-8 parts of sophora flower bud, 2-5 parts of fructus alpiniae oxyphyllae, 0.1-0.4 part of taurine, 0.1-0.4 part of soy isoflavone, 0.05-0.15 part of selenium-enriched yeast, and 0.05-0.15 part of bifidobacterium adolescentis. The medicinal and edible composition can improve the spatial learning and memory ability of dysmnesia model mice, shorten the escape latency and search distance of the mice, reduce the oxidative damage degree of brain tissues of the mice and inhibit the activity of acetylcholin esterase in the brain tissues, has a very good prevention and treatment effect on senile memory function decline, and can be used for preventing and treating senile amnesia, insomnia, anxiety and other symptoms.

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one sample from the subject to determine a value of the subject's exosomal profile or combined biomarker profile (lipids plus exosomal cargo) and comparing the value of the subject's exosomal or combined biomarker profile with the value of a normal exosomal or biomarker profile, respectively. A change in the value of the subject's exosomal or combined biomarker profile, including a change in the subject's exosomal or combined biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

The invention discloses a diabetic rat memory dysfunction testing system based on a ginkgo leaf extract. Comprising a surrounding module, a supporting face module fixedly connected to the interior of the surrounding module, a safety area module installed at the bottom of the surrounding module, an obstacle limiting area module slidably connected to the lower portion of the supporting face module, and an ultrasonic induction module installed on the inner wall of the surrounding module. The method comprises the following steps of: driving rats through an ultrasonic induction module inside a surrounding module by using audio disgusted by the rats as a driving factor, enabling the rats to avoid sound intervention of the ultrasonic induction module, and stopping the sound until the rats search or arrive at a safe area module through external auxiliary learning, so that the rats form learning memory; when a follow-up dysmnesia test is carried out, blood in a rat body is not influenced by temperature difference changes at the moment, actual detection data are more accurate, meanwhile, two training modes can be adopted for testing, and the testing accuracy is further improved.

The invention relates to a drug for treating senile dementia. The effective component of the drug is brilliant blue G, the molecular formula of the brilliant blue G is 47H48N3NaO7S2, the molecular weight is 854.02, the structural formula of the brilliant blue G is as shown in the specification; the drug can be used for effectively alleviating the symptoms of senile dementia, relieving memory dysfunction of senile dementia, relieving cognitive disorder of senile dementia and preventing neuron damage caused by senile dementia, and the drug has high efficiency and safety for treating the senile dementia.

The invention provides an RNAi adeno-associated virus for inhibiting Slc2a1 and a preparation method of the RNAi adeno-associated virus, wherein nucleic acid used by the RNAi is designed aiming at three interference sites on the Slc2a1. The adeno-associated virus disclosed by the invention can be used for remarkably and specifically inhibiting the expression of microglial cells Glut1; the mouse space learning and memory dysfunction caused by stress is obviously improved; the polarization of stress-induced microglial cells M1 can be inhibited, and the content of inflammatory factors in the hippocampus can be reduced; the compound is further applied to treatment of irritable learning and memory impairment, neuroinflammation and other diseases.

The invention discloses a pulse-activating compound extract and a preparation method thereof and application of the pulse-activating compound extract in the preparation of a medicine and a health product for improving memory. The pulse-activating compound extract comprises the following raw medicinal materials: ginseng, radix ophiopogonis, and Chinese magnoliavine. The weight ratio of ginseng to radix ophiopogonis to Chinese magnoliavine is 3:2:1. After alcohol extraction of the pulse-activating formula, dysmnesia caused by scopolamine can be improved, and memory function of normal Kunming mouse can be remarkably improved. The pulse-activating compound extract can be applied in the preparation of a medicine and a health product for improving memory.